Combination Chemotherapy in Treating Patients With Sarcoma (NCT00662233) | Clinical Trial Compass
CompletedEarly Phase 1
Combination Chemotherapy in Treating Patients With Sarcoma
United States28 participantsStarted 1991-10
Plain-language summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
PURPOSE: This clinical trial is studying how well combination chemotherapy works in treating patients with sarcoma.
Who can participate
Age range
21 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Diagnosis of any of the following:
* High-grade nonmetastatic, nonrhabdomyosarcomatous soft tissue sarcomas (excluding undifferentiated sarcoma and Ewing sarcoma)
* Small round cell sarcomas (excluding primitive neuroectodermal tumors of soft tissue) (closed to accrual)
* Undifferentiated sarcomas (closed to accrual)
* Rhabdomyosarcomas (excluding non-parameningeal head tumors, vaginal or stage I paratesticular) (closed to accrual)
* All alveolar rhabdomyosarcomas (closed to accrual)
* No evidence distant metastatic disease (i.e., lung, bone, bone marrow)
* Local or regional nodal disease allowed
* No spindle cell tumors of bone
* Primary lesions do not have to be resectable
PATIENT CHARACTERISTICS:
* Creatinine ≤1.5 mg/dL OR creatinine clearance \> 60 mL/min/
* AST/ALT \< 2 times upper limit of normal (ULN)
* Total bilirubin \< 2 times ULN
* LVEF ≥ 45%
* No prior history of cancer
* Not pregnant or nursing
* Negative pregnancy test
PRIOR CONCURRENT THERAPY:
* Patients who have undergone radiation therapy after initial surgery are eligible but must have evaluation for metastatic disease within 2 weeks of starting chemotherapy
* No prior chemotherapy
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Efficacy in terms of long-term disease-free survival